LENZ Therapeutics (LENZ) Assets Average (2021 - 2026)

LENZ Therapeutics (LENZ) has 6 years of Assets Average data on file, last reported at $289.2 million in Q1 2026.

• Assets Average for Q1 2026 came in at $289.2 million, up 38.86% year-over-year; the trailing twelve-month figure through Mar 2026 was $289.2 million (up 38.86% YoY), and the FY2025 annual result was $260.6 million, up 82.43% from the prior year.
• Assets Average climbed to $289.2 million in Q1 2026 per LENZ's latest filing, from $258.3 million in the prior quarter.
• Over five years, Assets Average peaked at $390.3 million in Q1 2022 and troughed at $143.8 million in Q1 2024.
• A 5-year average of $262.0 million and a median of $258.3 million in 2025 frame the typical range for Assets Average.
• The sharpest annual moves came in 2024 and 2025: Assets Average sank 54.47% in 2024, then soared 44.79% in 2025.
• A 5-year view of Assets Average shows it stood at $328.4 million in 2022, then slumped by 48.75% to $168.3 million in 2023, then surged by 30.51% to $219.7 million in 2024, then rose by 17.59% to $258.3 million in 2025, then advanced by 11.97% to $289.2 million in 2026.
• Business Quant data shows LENZ's Assets Average at $289.2 million in Q1 2026, $258.3 million in Q4 2025, and $214.0 million in Q3 2025.